REGAINE® for women The only clinically proven treatment for female pattern hair loss

Clinical photographs

Clinical photographs of female patient treated with 2% REGAINE® solution1

In a randomized, placebo-controlled trial of 2% REGAINE® solution in 154 patients with female pattern hair loss:

  • 2% REGAINE® group was significantly superior to placebo at each evaluation time point (p < 0.05)1
  • hair count and growth and benefit from treatment in 2% REGAINE® group was significantly superior to placebo1

Hair growth

Adapted from Lucky et al1

REGAINE® for women - pivotal trial

A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
Lucky AW, et al. J Am Acad Dermatol 2004; 50:541–53.

OBJECTIVE:
To compare the efficacy and safety of 5% and 2% topical minoxidil (REGAINE®) solutions and placebo in the treatment of female pattern hair loss.

METHODS:
48-week, double-blind, placebo-controlled, randomized, multicentre trial.

A total of 381 women (18-49 years old) with female pattern hair loss applied 5% topical minoxidil solution (n=153), 2% topical minoxidil solution (n=154) or placebo (vehicle for 5% solution; n=74) twice daily. Primary efficacy variables were change in nonvellus hair count at week 48, and patient and investigator assessments of change in hair growth/scalp coverage at week 48.

RESULTS:
The 2% REGAINE® group demonstrated superiority over placebo for hair count and investigator assessment of hair growth/scalp coverage at week 48; differences in patient assessment of hair growth at week 48 were not significantly different from placebo.

2% REGAINE® helped improve psychosocial perceptions of hair loss in women with female pattern hair loss.

CONCLUSION:
Application of 2% REGAINE® solution was superior to placebo for assessments of nonvellus hair counts and investigator assessment of hair growth/scalp coverage at week 48.

“With the introduction of numerous herbal remedies for hair loss, of which most have not been tested in randomized, double-blind, placebo-controlled trials, it is important to describe well-controlled trials that demonstrate the efficacy and safety of topical drugs”.

NB: 5% minoxidil is not licensed for use in women.

Click through to Pubmed http://www.ncbi.nlm.nih.gov/pubmed/15034503 .